| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $3.88 | - | - |
| Q1'26 | $2.33 | $2.87 | +23.2% |
| Q3'25 | $3.17 | $2.51 | -20.9% |
| Q2'25 | $2.75 | $2.95 | +7.3% |
| Q1'25 | $2.02 | $2.00 | -1.0% |
| Q4'24 | $2.13 | $2.24 | +5.4% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $3.5B | - | - |
| Q1'26 | $3.4B | $3.4B | +1.8% |
| Q3'25 | - | $3.4B | - |
| Q2'25 | - | $3.4B | - |
| Q1'25 | - | $3.2B | - |
| Q4'24 | - | $3.3B | - |
Market Data
DVA is currently trading at $235.00, giving DaVita Inc. a market cap of 14.95B and a P/E ratio of 19.1. Today's range spans $228.43–$235.00, with shares opening at $230.91 and moving up $2.20 (0.9%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 87/100.
Over the past year DVA has traded between $101.00 and $239.64 - the current price is +132.7% off the 52-week low and -1.9% from the high. 14 analysts cover the stock with a Hold consensus and a mean 12-month target of $197.14 (range $145.00–$235.00), implying downside of -16.1%.
DVA is scoring 86/100 technically (BUY) and sits at $235.00 - near 52-week highs in its $101.00–$239.64 annual range. Sentiment at 87/100 is bullish. At 14.95B in Healthcare market cap The current P/E ratio stands at 19.1., this is the tier where earnings revision cycles have the most impact on price: upward revisions in a large-cap company with bullish momentum tend to attract analyst upgrades, which in turn attract new institutional mandates.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (87/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $235.00 (near 52-week highs), DVA's position within the $101.00–$239.64 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).